Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the second quarter ended June 30, 2014 and provided an update on recent corporate events.
“Since the beginning of this year, ganetespib has reached several important clinical milestones across studies and cancer types, including encouraging results from the GALAXY-1 and ENCHANT Phase 2 studies in lung and breast cancer, and graduation to the Phase 3 extension in the AML LI-1 trial,” said Keith Gollust, Chairman of the Executive Committee of Synta.
Help employers find you! Check out all the jobs and post your resume.
